GALT — Galectin Therapeutics Share News
0.000.00%
Last trade - 00:00- $340.87m
- $465.30m
Galectin Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Galectin Therapeutics Announces $60 Million Credit Line From Richard E. Uihlein Sufficient To Cover Expected Expenditures Through 2024
Brief: Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations At The Easl International Liver Congress 2022
Galectin Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Galectin Therapeutics Inc - QTRLY Loss Per Share $0.17
Brief: Galectin Therapeutics Reports Financial Results For The Quarter Ended March 31
Galectin Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Galectin jumps after positive safety update on liver disease therapy
Brief: Galectin Reports Positive Outcome Of Its First Data And Safety Monitoring Board Meeting For Navigate
Brief: Galectin Reports Positive Outcome Of First Data And Safety Monitoring Board For Study Of Belapectin
Galectin Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Galectin Says Will Require More Cash To Fund Operations After March 31, 2023
Galectin Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE- 3M, IBM, airline stocks
Brief: Galectin Therapeutics - NAVIGATE Trial In NASH Cirrhosis Now Underway In All Countries Originally Selected Full Enrollment Expected By Mid-2022
Brief: Galectin Therapeutics Reports Qtrly Loss Per Share $0.14
Brief: Galectin Therapeutics Qtrly Loss Per Share $0.14
Brief: Galectin Therapeutics Inc Says Co And Richard E. Uihlein Entered Into A Loan Agreement In Aggregate Of $20.0 Mln
Brief: Galectin Therapeutics Announces $20 Million Convertible Debt Financing From Its Chairman, Richard E. Uihlein